Packgene Biotech271PackGene Biotech was founded in 2014 by visionary scientists dedicated to making life-changing gene therapies universally accessible. Recognizing the immense promise and critical challenges of AAV vector production, we set out to revolutionize AAV manufacturing and broader gene therapy production through innovation, scalability, and cost-efficiency.
As a world-leading CRO and CDMO, we excel in providing comprehensive AAV vector, mRNA, plasmid DNA, and lentiviral vector solutions. Our offerings support early-stage drug discovery, preclinical development, and clinical trials with reliable, cost-effective, and scalable production. We've developed the groundbreaking π-Alpha 293 AAV High-yield Platform, which amplifies AAV production up to 10-fold, reaching 1E+17vg per batch. We also provide seamless, end-to-end plasmid, mRNA and LNP products and services from research to GMP.
